Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Sickle Cell Disease
Interventions
DRUG

Oral Decitabine and Tetrahydrouridine

Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks

DRUG

Placebo

Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.

Trial Locations (1)

60612

University of Illinois at Chicago, Chicago

All Listed Sponsors
collaborator

University of Illinois at Chicago

OTHER

lead

Yogen Saunthararajah

OTHER

NCT01685515 - Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease | Biotech Hunter | Biotech Hunter